Brain insulin resistance: role in neurodegenerative disease and potential for targeting
出版年份 2020 全文链接
标题
Brain insulin resistance: role in neurodegenerative disease and potential for targeting
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 29, Issue 4, Pages 333-348
出版商
Informa UK Limited
发表日期
2020-03-16
DOI
10.1080/13543784.2020.1738383
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study
- (2020) Francesco Vadini et al. INTERNATIONAL JOURNAL OF OBESITY
- Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease
- (2020) Jelena Osmanovic Barilar et al. JOURNAL OF NEURAL TRANSMISSION
- A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice
- (2020) Tian Li et al. NEUROPHARMACOLOGY
- The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease
- (2020) Lingyu Zhang et al. Journal of Parkinsons Disease
- The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD
- (2020) Cheng Li et al. Brain and Behavior
- Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease
- (2019) Dilan Athauda et al. JAMA Neurology
- DA-JC1 improves learning and memory by antagonizing Aβ31–35-induced circadian rhythm disorder
- (2019) Li Wang et al. Molecular Brain
- Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease
- (2019) Liping Zhang et al. Journal of Parkinsons Disease
- Liraglutide and its Neuroprotective Properties—Focus on Possible Biochemical Mechanisms in Alzheimer’s Disease and Cerebral Ischemic Events
- (2019) Michał Wiciński et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways
- (2019) Holly Green et al. CNS DRUGS
- Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β
- (2019) Mei Zhou et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
- (2019) Grazia Daniela Femminella et al. Trials
- Extracellular Vesicle Biomarkers Track Cognitive Changes Following Intranasal Insulin in Alzheimer’s Disease
- (2019) Maja Mustapic et al. JOURNAL OF ALZHEIMERS DISEASE
- Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression
- (2019) Xinyi Wang et al. CELL RESEARCH
- D‐Ser2‐oxyntomodulin ameliorated Aβ31‐35‐induced circadian rhythm disorder in mice
- (2019) Li Wang et al. CNS Neuroscience & Therapeutics
- Role of the Blood-Brain Barrier in Central Nervous System Insulin Resistance
- (2019) Elizabeth M. Rhea et al. Frontiers in Neuroscience
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models
- (2019) Zhen Qiang Zhang et al. PEPTIDES
- Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences
- (2019) Domenico Sergi et al. Frontiers in Aging Neuroscience
- A dual GLP-1 and Gcg receptor agonist rescues spatial memory and synaptic plasticity in APP/PS1 transgenic mice
- (2019) Zhao-Jun Wang et al. HORMONES AND BEHAVIOR
- A resurrection of aducanumab for Alzheimer's disease
- (2019) Lon Schneider LANCET NEUROLOGY
- Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease
- (2019) Geisa Nogueira Salles et al. NEUROPHARMACOLOGY
- Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease
- (2018) Jingjing Tai et al. BRAIN RESEARCH
- Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus
- (2018) Rui-Fang Wang et al. EPILEPSY RESEARCH
- DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease
- (2018) Yue Cao et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease
- (2018) Tian Li et al. HIPPOCAMPUS
- Glucose-Dependent Insulinotropic Polypeptide Mitigates 6-OHDA-Induced Behavioral Impairments in Parkinsonian Rats
- (2018) Yu-Wen Yu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease
- (2018) Andre F Batista et al. JOURNAL OF PATHOLOGY
- Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
- (2018) Steven E. Arnold et al. Nature Reviews Neurology
- Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
- (2018) Liping Zhang et al. NEUROPEPTIDES
- Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease
- (2018) Peng Feng et al. NEUROPHARMACOLOGY
- Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models
- (2018) Christian Hölscher NEUROPHARMACOLOGY
- Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer’s disease
- (2018) Ana Knezovic et al. NEUROPHARMACOLOGY
- Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets
- (2018) Marcelo N.N. Vieira et al. NEUROPHARMACOLOGY
- The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia
- (2018) Liying Yang et al. Frontiers in Neuroscience
- D-Ala2GIP Facilitated Synaptic Plasticity and Reduces Plaque Load in Aged Wild Type Mice and in an Alzheimer's Disease Mouse Model
- (2018) Emilie Faivre et al. JOURNAL OF ALZHEIMERS DISEASE
- The Novel DA–CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model
- (2018) Theodora Panagaki et al. JOURNAL OF ALZHEIMERS DISEASE
- Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease
- (2018) Kathleen T. Watson et al. BEHAVIOURAL BRAIN RESEARCH
- Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis
- (2018) Michaela E. Johnson et al. TRENDS IN NEUROSCIENCES
- Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors
- (2017) Lindsay Joy Spielman et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Effect of D-Ala 2 GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice
- (2017) Mahip K. Verma et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease
- (2017) Ziyue Yuan et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
- (2017) Yanwei Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
- (2017) Choon Bae et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial
- (2017) Suzanne Craft et al. JOURNAL OF ALZHEIMERS DISEASE
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice
- (2017) Shuyi Chen et al. NEUROCHEMICAL RESEARCH
- A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease
- (2017) Jaishree Jalewa et al. NEUROPHARMACOLOGY
- 16S rRNA Next Generation Sequencing Analysis Shows Bacteria in Alzheimer’s Post-Mortem Brain
- (2017) David C. Emery et al. Frontiers in Aging Neuroscience
- Parkinson disease
- (2017) Werner Poewe et al. Nature Reviews Disease Primers
- Intranasal Insulin Administration Dose-Dependently Modulates Verbal Memory and Plasma Amyloid-β in Memory-Impaired Older Adults
- (2017) Mark A. Reger et al. JOURNAL OF ALZHEIMERS DISEASE
- GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease
- (2017) Yazhou Li et al. JOURNAL OF ALZHEIMERS DISEASE
- Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells
- (2017) Theodora Panagaki et al. Scientific Reports
- The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
- (2016) Henrik H. Hansen et al. BRAIN RESEARCH
- A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson′s disease by increasing expression of BNDF
- (2016) Chenhui Ji et al. BRAIN RESEARCH
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells
- (2016) Jaishree Jalewa et al. JOURNAL OF NEUROCHEMISTRY
- Understanding Dopaminergic Cell Death Pathways in Parkinson Disease
- (2016) Patrick P. Michel et al. NEURON
- Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model
- (2016) Yanwei Li et al. NEUROPHARMACOLOGY
- A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson’s disease by reducing chronic inflammation in the brain
- (2016) Lijun Cao et al. NEUROREPORT
- A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat
- (2016) Ling Han et al. NEUROREPORT
- Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease
- (2016) Henrik H. Hansen et al. PLoS One
- Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease
- (2016) Chenhui Ji et al. REVIEWS IN THE NEUROSCIENCES
- Reappraisal of GIP Pharmacology for Metabolic Diseases
- (2016) Brian Finan et al. TRENDS IN MOLECULAR MEDICINE
- In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial
- (2016) Michael Gejl et al. Frontiers in Aging Neuroscience
- Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice
- (2015) Paula L. McClean et al. BEHAVIOURAL BRAIN RESEARCH
- Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
- (2015) Celeste M. Karch et al. BIOLOGICAL PSYCHIATRY
- Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain
- (2015) Kristy M. Heppner et al. ENDOCRINOLOGY
- Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
- (2015) WeiZhen Liu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes
- (2015) M Christensen et al. INTERNATIONAL JOURNAL OF OBESITY
- Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
- (2015) W. Liu et al. NEUROSCIENCE
- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
- (2015) Simon C. Cork et al. Molecular Metabolism
- Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging
- (2014) Grazia D. Femminella et al. Alzheimers & Dementia
- Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases
- (2014) Christian Hölscher BIOCHEMICAL SOCIETY TRANSACTIONS
- Advances in the prevention of Alzheimer's disease and dementia
- (2014) A. Solomon et al. JOURNAL OF INTERNAL MEDICINE
- Inflammation-sleep interface in brain disease: TNF, insulin, orexin
- (2014) Ian A Clark et al. Journal of Neuroinflammation
- The medical treatment of Parkinson disease from James Parkinson to George Cotzias
- (2014) Stanley Fahn MOVEMENT DISORDERS
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
- (2014) Paula L. McClean et al. NEUROPHARMACOLOGY
- TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys
- (2013) Mychael V. Lourenco et al. Cell Metabolism
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence
- (2013) Jessica Freiherr et al. CNS DRUGS
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress
- (2013) Mohit K. Sharma et al. JOURNAL OF NEUROCHEMISTRY
- Trophic Factor Gene Therapy for Parkinson's Disease
- (2013) Jeffrey H. Kordower et al. MOVEMENT DISORDERS
- Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation
- (2013) N. K. Patel et al. NEUROLOGY
- Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
- (2013) Paula L. McClean et al. NEUROPHARMACOLOGY
- GDNF, NGF and BDNF as therapeutic options for neurodegeneration
- (2013) Shelley J. Allen et al. PHARMACOLOGY & THERAPEUTICS
- Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model
- (2013) Vadivel Parthsarathy et al. PLoS One
- A Novel Glucagon-Related Peptide (GCRP) and Its Receptor GCRPR Account for Coevolution of Their Family Members in Vertebrates
- (2013) Cho Rong Park et al. PLoS One
- Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
- (2013) Katharine Eakin et al. PLoS One
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
- (2013) Emilie Faivre et al. Alzheimers Research & Therapy
- Epidemiology of Alzheimer Disease
- (2013) R. Mayeux et al. Cold Spring Harbor Perspectives in Medicine
- Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice
- (2012) Lital Rachmany et al. AGE
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Risk of Parkinson Disease Onset in Patients With Diabetes: A 9-year population-based cohort study with age and sex stratifications
- (2012) Y. Sun et al. DIABETES CARE
- The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain
- (2012) Vadivel Parthsarathy et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers
- (2012) Theresa R. Bomfim et al. JOURNAL OF CLINICAL INVESTIGATION
- Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline
- (2012) Konrad Talbot et al. JOURNAL OF CLINICAL INVESTIGATION
- GLP-1 secretion by microglial cells and decreased CNS expression in obesity
- (2012) Camilla Kappe et al. Journal of Neuroinflammation
- Insulin in the Brain: Sources, Localization and Functions
- (2012) Rasoul Ghasemi et al. MOLECULAR NEUROBIOLOGY
- Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats
- (2012) Wei-Na Han et al. NEUROBIOLOGY OF AGING
- The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease
- (2012) Caitriona M. Long-Smith et al. NEUROMOLECULAR MEDICINE
- Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway
- (2012) M.-D. Wang et al. NEUROSCIENCE
- The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease
- (2012) A.M. Duffy et al. NEUROSCIENCE
- The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
- (2011) Asger Lund et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment
- (2011) Suzanne Craft ARCHIVES OF NEUROLOGY
- Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease
- (2011) Christian Hölscher BIOCHEMICAL SOCIETY TRANSACTIONS
- Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
- (2011) Victor A. Gault et al. CLINICAL SCIENCE
- Diabetes and Risk of Parkinson's Disease
- (2011) Q. Xu et al. DIABETES CARE
- An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
- (2011) S. Madsbad et al. DIABETES OBESITY & METABOLISM
- (Val8) glucagon-like peptide-1 prevents tau hyperphosphorylation, impairment of spatial learning and ultra-structural cellular damage induced by streptozotocin in rat brains
- (2011) Lin Li et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Lixisenatide for type 2 diabetes mellitus
- (2011) Mikkel Christensen et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain
- (2011) A. Hamilton et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Potential therapeutic uses of BDNF in neurological and psychiatric disorders
- (2011) Alan H. Nagahara et al. NATURE REVIEWS DRUG DISCOVERY
- Glucose tolerance status and risk of dementia in the community: The Hisayama Study
- (2011) T. Ohara et al. NEUROLOGY
- Neurotoxin-based models of Parkinson's disease
- (2011) J. Bové et al. NEUROSCIENCE
- Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 Diabetes
- (2010) Laura D. Baker et al. ARCHIVES OF NEUROLOGY
- Role of the glucose-dependent insulinotropic polypeptide and its receptor in the central nervous system: therapeutic potential in neurological diseases
- (2010) Cláudia P. Figueiredo et al. BEHAVIOURAL PHARMACOLOGY
- Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance
- (2010) D. W. Porter et al. DIABETES OBESITY & METABOLISM
- Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice
- (2010) David W. Porter et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides
- (2010) Niels Vrang et al. PROGRESS IN NEUROBIOLOGY
- Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
- (2009) Shyeilla V. Dhuria et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Incretin-based therapies for type 2 diabetes mellitus
- (2009) Julie A. Lovshin et al. Nature Reviews Endocrinology
- Systemic inflammation and disease progression in Alzheimer disease
- (2009) C. Holmes et al. NEUROLOGY
- Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease
- (2009) M. Blurton-Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Systemic Inflammation Induces Acute Behavioral and Cognitive Changes and Accelerates Neurodegenerative Disease
- (2008) Colm Cunningham et al. BIOLOGICAL PSYCHIATRY
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
- Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease
- (2008) Alexander Harkavyi et al. Journal of Neuroinflammation
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
- (2008) Clive Holmes et al. LANCET
- New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer’s disease?
- (2008) Christian Hölscher et al. NEUROBIOLOGY OF AGING
- Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling
- (2008) Aileen M. Moloney et al. NEUROBIOLOGY OF AGING
- Towards a pathway definition of Parkinson’s disease: a complex disorder with links to cancer, diabetes and inflammation
- (2008) Linda B. Moran et al. NEUROGENETICS
- Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
- (2008) Claire Henchcliffe et al. Nature clinical practice. Neurology
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now